ImmunoCellular names new CEO to take cancer vaccine venture to next level
This article was originally published in Scrip
Executive Summary
ImmunoCellular Therapeutics has hired Andrew Gengos as its new president and CEO to take the Los Angeles-based company into a stage of business development that matches the clinical development status for the firm's Phase IIb dendritic cell-based vaccine ICT-107 targeting multiple tumor-associated antigens for glioblastoma.